Core Viewpoint - BioArctic AB will release its fourth quarter report for October - December 2025 on February 18, 2026, at 08:00 a.m. CET, followed by a presentation for investors, analysts, and media at 09:30 a.m. CET [1][2]. Company Information - BioArctic AB is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's disease [2]. - The company developed Leqembi® (lecanemab), the first drug proven to slow the progression of early Alzheimer's disease and reduce cognitive impairment [2]. - BioArctic has a diverse research portfolio, including antibodies targeting Parkinson's disease and ALS, as well as additional Alzheimer's projects [2]. - The company utilizes its proprietary BrainTransporter™ technology to enhance treatment efficacy by transporting antibodies across the blood-brain barrier [2]. Event Details - The presentation on the fourth quarter report will include comments from CEO Gunilla Osswald and CFO Anders Martin-Löf, followed by a Q&A session [1]. - Participants can join via webcast or teleconference, with options to submit questions during the event [1][2].

Core Insights - Lecanemab has received Marketing Authorization in the EU, marking it as the first therapy targeting the underlying cause of Alzheimer's disease to be approved in this region [1][2] - The treatment is specifically indicated for adult patients with mild cognitive impairment and mild dementia due to Alzheimer's disease who are ApoE ε4 non-carriers or heterozygotes with confirmed amyloid pathology [1][2] - The approval applies to all 27 EU Member States, as well as Iceland, Liechtenstein, and Norway [1][3] Company Overview - Eisai Co., Ltd. and Biogen Inc. are collaborating on the development and commercialization of lecanemab, with Eisai leading the global development and regulatory submissions [2][8] - The approval of lecanemab in the EU is the thirteenth approval globally, following its benefits to thousands of patients in the U.S., Japan, and other regions [2][6] - Eisai aims to work with national reimbursement authorities and healthcare providers to ensure access to lecanemab for eligible patients as soon as possible [2] Clinical Data - The authorization was based on Phase 3 data from the Clarity AD clinical trial, which involved 1,795 patients with early Alzheimer's disease [4][6] - In the trial, lecanemab reduced clinical decline on the CDR-SB scale by 31% at 18 months compared to placebo [4][6] - The secondary endpoint showed a 33% less decline in daily living activities for patients treated with lecanemab compared to placebo [4][6] Market Context - Alzheimer's disease currently affects an estimated 15.2 million people with mild cognitive impairment and 6.9 million with mild dementia in Europe, indicating a significant unmet need for effective treatments [1][6] - Lecanemab is the only approved Aβ monoclonal antibody that preferentially binds and clears toxic protofibrils, which are key contributors to neuronal injury in Alzheimer's disease [1][4] - The approval of lecanemab represents a landmark advancement in a field that has seen little innovation over the past two decades [2][6]

Core Insights - Lecanemab has received Marketing Authorization in the EU, marking it as the first therapy targeting the underlying cause of Alzheimer's disease to be approved in this region [1][2][6] - The treatment is specifically indicated for adult patients with mild cognitive impairment and mild dementia due to Alzheimer's disease who are non-carriers or heterozygotes of the ApoE ε4 gene [1][2][6] - The approval applies to all 27 EU Member States, as well as Iceland, Liechtenstein, and Norway [1][2] Company Overview - Eisai and Biogen are collaborating on the development and commercialization of lecanemab, with Eisai leading global regulatory submissions and having final decision-making authority [2][10] - The approval of lecanemab in the EU is the thirteenth approval globally, following its success in the U.S., Japan, and other regions [2][6] - Eisai aims to work with national reimbursement authorities to ensure access to lecanemab for eligible patients as soon as possible [2] Clinical Data - The authorization was based on Phase 3 data from the Clarity AD clinical trial, which involved 1,795 patients and demonstrated a 31% reduction in clinical decline on the CDR-SB scale at 18 months compared to placebo [6][7] - The trial showed that lecanemab reduced the mean change from baseline on the CDR-SB score by 0.535 points compared to placebo [6][7] - Secondary endpoints indicated a 33% less decline in the ADCS MCI-ADL score for lecanemab compared to placebo at 18 months [7] Market Context - Alzheimer's disease currently affects an estimated 15.2 million people with mild cognitive impairment and 6.9 million with mild dementia in Europe, highlighting a significant unmet need for effective treatments [1][2][6] - Lecanemab is positioned as a groundbreaking treatment in a field that has seen little innovation over the past two decades [2][6] Safety Profile - Common adverse reactions reported in the clinical trial included infusion-related reactions (26%), ARIA-H (13%), headache (11%), and ARIA-E (9%) [7] - The treatment is subject to additional monitoring to quickly identify new safety information [4]